Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination.

Antimicrobial Agents and Chemotherapy
Yoke-Lin LoBruce Charles

Abstract

The present study determined the pharmacokinetic profile of vancomycin in premature Malaysian infants. A one-compartment infusion model with first-order elimination was fitted to serum vancomycin concentration data (n = 835 points) obtained retrospectively from the drug monitoring records of 116 premature newborn infants. Vancomycin concentrations were estimated by a fluorescence polarization immunoassay. Population and individual estimates of clearance and distribution volume and the factors which affected the variability observed for the values of these parameters were obtained using a population pharmacokinetic modeling approach. The predictive performance of the population model was evaluated by visual inspections of diagnostic plots and nonparametric bootstrapping with replacement. Dosing guidelines targeting a value of > or =400 for the area under the concentration-time curve over 24 h in the steady state divided by the MIC (AUC(24)/MIC ratio) were explored using Monte Carlo simulation. Body size (weight), postmenstrual age, and small-for-gestational-age status are important factors explaining the between-subject variability of vancomycin pharmacokinetic parameter values for premature neonates. The typical population para...Continue Reading

References

Aug 1, 1992·Journal of Pharmacological and Toxicological Methods·Y ChenP J Ravenscroft
Apr 1, 1992·British Journal of Obstetrics and Gynaecology·S A HinchliffeD Van Velzen
Jul 1, 1991·DICP : the Annals of Pharmacotherapy·L M AlbrechtD J Edwards
Oct 1, 1990·American Journal of Perinatology·D RobinsonJ E Robillard
Mar 1, 1993·Fetal Diagnosis and Therapy·A PachìM A Castello
May 1, 1996·Clinical Pharmacokinetics·N H Holford
Apr 2, 1999·Pediatrics·J P Guignard, A Drukker
May 9, 2000·Clinical Pharmacology and Therapeutics·M de HoogJ N van den Anker
Jan 9, 2001·Early Human Development·M Mongelli, A Biswas
Sep 11, 2001·Journal of Clinical Pharmacology·E V CapparelliJ D Connor
May 16, 2003·American Journal of Obstetrics and Gynecology·Lori E SilverLony C Castro
Jun 17, 2003·Biological & Pharmaceutical Bulletin·Takuya IwamotoMichio Kojima
Mar 30, 2004·Antimicrobial Agents and Chemotherapy·Toshimi KimuraKazuo Yago
May 14, 2004·Clinical Pharmacokinetics·Matthijs de HoogJohn N van den Anker
Aug 26, 2004·The Annals of Pharmacotherapy·Ene I Ette, Paul J Williams
Nov 1, 2005·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Yoshio Kobayashi
Nov 12, 2005·The Pediatric Infectious Disease Journal·Daniel A C FrattarelliJacob V Aranda
Mar 2, 2006·The Journal of Antimicrobial Chemotherapy·Curtis G GemmellUNKNOWN Joint Working Party of the British Society for Joint Working Party of the British Society for Antimicrobial Chemotherapy, Ho
Jul 28, 2006·British Journal of Clinical Pharmacology·Brian J AndersonNicholas H G Holford
Apr 17, 2007·American Journal of Infection Control·Renato C CoutoFernando M Biscione
May 29, 2007·Therapeutic Drug Monitoring·Karel AllegaertFrancis de Zegher
Oct 5, 2007·Annual Review of Pharmacology and Toxicology·B J Anderson, N H G Holford
Mar 20, 2008·The Journal of Antimicrobial Chemotherapy·Kristjan O HelgasonCraig Ferguson
Sep 23, 2008·Archives of Disease in Childhood. Fetal and Neonatal Edition·R TiskumaraUNKNOWN Asia-Pacific Neonatal Infections Study
Dec 25, 2008·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Michael RybakDonald P Levine
Jul 10, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas P LodiseGeorge L Drusano

❮ Previous
Next ❯

Citations

Nov 28, 2012·Clinical Pharmacokinetics·Amélie MarsotNicolas Simon
Dec 14, 2011·Clinical Pharmacokinetics·Amélie MarsotNicolas Simon
Feb 9, 2012·Medical Mycology·Giovanni Salvatori, Silvia Campo
Aug 21, 2015·Expert Review of Clinical Pharmacology·Evelyne Jacqz-AigrainMike Sharland
Nov 10, 2012·Seminars in Fetal & Neonatal Medicine·Evelyne Jacqz-AigrainJohn N van den Anker
Dec 3, 2015·Pharmaceutical Research·Pyry A J VälitaloJ G Coen van Hasselt
Dec 12, 2012·British Journal of Clinical Pharmacology·Johan G C van HasseltAlwin D R Huitema
Aug 4, 2011·Pediatrics International : Official Journal of the Japan Pediatric Society·Mitsuru IrikuraTetsumi Irie
Sep 29, 2015·Journal of Clinical Pharmacology·Jiraganya Jj BhongsatiernCatherine M T Sherwin
Feb 8, 2016·British Journal of Clinical Pharmacology·J G Coen van HasseltPiet H van der Graaf
May 21, 2016·British Journal of Clinical Pharmacology·Sílvia M IllamolaJ G Coen van Hasselt
Oct 31, 2017·Therapeutic Drug Monitoring·Tõnis TasaIrja Lutsar
Mar 13, 2014·Antimicrobial Agents and Chemotherapy·Julianne KimAndrew Simor
Jan 21, 2016·Antimicrobial Agents and Chemotherapy·Stéphanie LerouxWei Zhao
Dec 9, 2015·Antimicrobial Agents and Chemotherapy·Esther J H JanssenCatherijne A J Knibbe
Mar 6, 2019·Antimicrobial Agents and Chemotherapy·Frank KloproggeJoseph F Standing
Jun 15, 2019·Journal of Veterinary Pharmacology and Therapeutics·Orhan CorumKamil Uney
Feb 6, 2017·British Journal of Clinical Pharmacology·Nick H G Holford, Brian J Anderson
May 15, 2013·Therapeutic Drug Monitoring·Wei Zhao, Evelyne Jacqz-Aigrain
Oct 22, 2014·Paediatrics & Child Health·Deonne Dersch-MillsKamran Yusuf
Jun 14, 2019·Journal of Veterinary Pharmacology and Therapeutics·Orhan CorumKamil Uney
May 19, 2021·Clinical Pharmacokinetics·Erin ChungWinnie Seto
Jun 23, 2021·European Journal of Drug Metabolism and Pharmacokinetics·Kannan SridharanMwila Mulubwa
Dec 4, 2021·Frontiers in Pharmacology·Muhammad Muaaz MunirMuhammad Usman

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

© 2021 Meta ULC. All rights reserved